DNA Encoded Library Market: Platforms and Services (2nd Edition) - Distribution by Application Area (Hit Generation / Identification, Hit to Lead, Hit Validation / Optimization and Other Application Areas), Therapeutic Area (Oncological Disorders, Immunological Disorders, Neurological Disorders, Respiratory Disorders, Dermatological Disorders, Cardiovascular Disorders, Infectious Diseases and Other Therapeutic Areas), End-users (Pharma / Biopharma Industry, Academic / Research Institute and Other End-users), Type of Payment Model Employed (Upfront Payment and Milestone Payment) and Key Geographical Regions (North America - US, Europe - UK, Germany, Denmark, France, Switzerland and Rest of the Europe, and Asia-Pacific - China): Industry Trends and Global Forecasts, 2023-2035
The global DNA encoded library market is expected to reach USD 840 million in 2023 anticipated to grow at a CAGR of 16% during the forecast period 2023-2035.
Over time, DNA encoded libraries have emerged as a resilient platform for drug discovery, streamlining the synthesis and screening of millions of small molecules in a unified investigation. These libraries comprise small molecules tagged with DNA, serving as unique identifiers or barcodes for identification purposes. The adoption of DNA encoded chemical libraries has experienced a notable surge recently, primarily attributed to their ability to expedite the drug discovery process by reducing the time and costs associated with traditional high-throughput screening methods.
The growing demand for novel therapies addressing complex diseases, particularly oncological and neurological disorders, has driven the rapid advancement of DNA encoded libraries. This heightened interest has been further amplified by increased adoption of DNA encoded chemical libraries among pharmaceutical and biotechnology companies, academic institutions, and contract research organizations. Consequently, these factors have significantly contributed to the burgeoning market growth within this sector.
Propelled by continual innovation in this field and substantial financial support from investors, it is expected that the DNA encoded library market will undergo substantial expansion throughout the forecasted period.
Report Coverage
Over time, DNA encoded libraries have emerged as a resilient platform for drug discovery, streamlining the synthesis and screening of millions of small molecules in a unified investigation. These libraries comprise small molecules tagged with DNA, serving as unique identifiers or barcodes for identification purposes. The adoption of DNA encoded chemical libraries has experienced a notable surge recently, primarily attributed to their ability to expedite the drug discovery process by reducing the time and costs associated with traditional high-throughput screening methods.
The growing demand for novel therapies addressing complex diseases, particularly oncological and neurological disorders, has driven the rapid advancement of DNA encoded libraries. This heightened interest has been further amplified by increased adoption of DNA encoded chemical libraries among pharmaceutical and biotechnology companies, academic institutions, and contract research organizations. Consequently, these factors have significantly contributed to the burgeoning market growth within this sector.
Propelled by continual innovation in this field and substantial financial support from investors, it is expected that the DNA encoded library market will undergo substantial expansion throughout the forecasted period.
Report Coverage
- An executive summary of the insights captured in our research. It presents a high-level view on the current scenario within the DNA-encoded libraries developers’ market and its evolution in the short-mid-term and long term.
- An introduction to the process of drug discovery and development. In addition, the chapter focuses on the concept of DNA-encoded libraries with information on the evolution of these libraries, advantages over other conventional drug discovery methods and the challenges associated with the same. It also features a brief discussion on the opportunities and the likely future trends in this field.
- A detailed overview of the current market landscape of DNA-encoded libraries, featuring information on type of pharmacological lead (macrocycles, natural products, peptides and small molecules), library size, method of library synthesis, type of therapeutic target and type of therapeutic area. In addition, the chapter provides an overview of DNA-encoded libraries developers and analysis based on parameters, such as year of establishment, company size, type of service offered (screening service / hit identification, hit optimization / validation, custom library design / synthesis, in-house drug development and DNA-encoded library service kits) and geographical location.
- An in-depth analysis and discussion on the various collaborations and partnerships inked between the players in the recent past; these include research collaborations, research and development agreements, licensing agreements, acquisitions, distribution agreements, service alliances, and other relevant agreements.
- Detailed profiles of the prominent service providers engaged in this domain. Each profile features a brief overview of company, information on its services associated with their DNA-Encoded library, recent developments and an informed future outlook.
- A case study on the therapeutic target(s) against which the DNA-encoded libraries are capable of identifying potential leads. Examples of such targets include undruggable cancer targets (special focus on GPCRs), DNA repair targets (special focus on PARP inhibitors) and other targets (such as alpha-1-acid glycoprotein (AGP), carbonic anhydrase IX, mitogen-activated protein kinase 14 (MAPK14), Neurokinin 3 (NK3), receptor?interacting protein 1 kinase (RIP1), soluble epoxide hydrolase (sEH) and interleukin 2).
- An overview of the initiatives taken by big pharma companies (such as Amgen, AstraZeneca, GSK, Novartis, Pfizer and Roche) involved in this domain, highlighting the key focus areas of these players along with information on the recent deals inked with the DNA-encoded library providers (if available). It also features company snapshots for each of the above-mentioned companies.
- An insightful market forecast analysis, highlighting likely growth of DNA-encoded libraries market till the year 2030, on the basis of likely licensing deal structures and agreements that are expected to be signed in the foreseen future. The market is segmented across distribution by application area, therapeutic area, end-users, type of payment model employed and key geographical regions
- AlphaMa
- DICE Therapeutics
- DyNAbind
- HitGen
- NovAliX
- Vipergen
- WuXi AppTec
- X-Chem
1. PREFACE
1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization
3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
3.5. Future Perspectives and Opportunity Areas
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)
5. BUSINESS MODEL ANALYSIS
5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks
12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
15.7. Anonymous
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
1.1. DNA Encoded Library Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Drug Development
3.3. Drug Discovery Process
3.3.1. Target Identification
3.3.2. Target Validation
3.3.3. Hit Generation
3.3.3.1. High-throughput Screening
3.3.3.2. Fragment-based Screening
3.3.3.3. Virtual Screening
3.3.3.4. DNA Encoded Library Screening
3.3.4. Lead Generation
3.3.5. Lead Optimization
3.4. Overview of DNA Encoded Libraries
3.4.1. Encoding Strategies for Library Construction
3.4.2. Historical Evolution of DNA Encoded Libraries
3.4.3. Comparison of Traditional Libraries and DNA Encoded Libraries
3.4.4. Key Advantages of DNA Encoded Libraries
3.4.5. Challenges and Limitations Associated with DNA Encoded Libraries
3.5. Future Perspectives and Opportunity Areas
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Encoded Library: Overall Market Landscape of Service Providers / Platform Providers / In-House Companies
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Company / Organization
4.2.6. Analysis by Library Size
4.2.7. Analysis by Library Synthesis Method(s)
4.2.8. Analysis by Library Screening Method(s)
4.2.9. Analysis by Type of Product(s) Offered
4.2.10. Analysis by Type of Service(s) Offered
4.2.10.1. Analysis by Type of Library Design Service(s) Offered
4.2.10.2. Analysis by Type of Library Screening Service(s) Offered
4.2.11. Analysis by Type of Pharmacological Lead(s)
4.2.12. Analysis by Therapeutic Target(s)
4.2.13. Analysis by Therapeutic Area(s)
4.2.14. Analysis by End-user(s)
5. BUSINESS MODEL ANALYSIS
5.1. Chapter Overview
5.2. DNA Encoded Library Companies: Business Model Analysis
5.2.1. Analysis by Operational Model
5.2.1.1. Analysis by Company Size and Operational Model
5.2.1.2. Analysis by Location of Headquarters and Operational Model
5.2.2. Analysis by Business Model
5.2.2.1. Analysis by Service Centric Model
5.2.2.2. Analysis by Product Centric Model
5.3. Concluding Remarks
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Company Competitiveness Analysis: DNA Encoded Library Service Providers / Platform Providers / In-House Companies
6.4.1. DNA Encoded Library Companies based in North America
6.4.2. DNA Encoded Library Companies based in Europe
6.4.3. DNA Encoded Library Companies based in Asia-Pacific
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. AlphaMa
7.2.1. Company Overview
7.2.2. DNA Encoded Library Platform and Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DICE Therapeutics
7.3.1. Company Overview
7.3.2. DNA Encoded Library Platform and Service Portfolio
7.3.3. Recent Developments and Future Outlook
7.4. DyNAbind
7.4.1. Company Overview
7.4.2. DNA Encoded Library Platform and Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. HitGen
7.5.1. Company Overview
7.5.2. DNA Encoded Library Platform and Service Portfolio
7.5.3. Recent Developments and Future Outlook
7.6. NovAliX
7.6.1. Company Overview
7.6.2. DNA Encoded Library Platform and Service Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Vipergen
7.7.1. Company Overview
7.7.2. DNA Encoded Library Platform and Service Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. WuXi AppTec
7.8.1. Company Overview
7.8.2. DNA Encoded Library Platform and Service Portfolio
7.8.3. Recent Developments and Future Outlook
7.9. X-Chem
7.9.1. Company Overview
7.9.2. DNA Encoded Library Platform and Service Portfolio
7.9.3. Recent Developments and Future Outlook
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. DNA Encoded Libraries: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Focus Area
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Type of Partner
8.3.6.1 Analysis by Partner Company Size
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Analysis by Geography
8.3.8.1. International and Local Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. DNA Encoded Libraries: Funding and Investment Analysis
9.3.1. Analysis of Instances by Year of Funding
9.3.2. Analysis of Amount Invested by Year of Funding
9.3.3. Analysis of Instances by Type of Funding
9.3.4. Analysis of Amount Invested by Type of Funding
9.3.5. Most Active Players: Analysis by Number of Funding Instances
9.3.6. Most Active Players: Analysis by Amount Raised
9.3.7. Most Active Investors: Analysis by Number of Instances
9.3.8. Analysis by Geography
9.3.9. Concluding Remarks
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. DNA Encoded Libraries: Patent Analysis
10.3.1. Analysis by Patent Publication Year
10.3.2. Analysis by Patent Application Year
10.3.3. Analysis by Type of Patent and Publication Year
10.3.4. Analysis by Patent Jurisdiction
10.3.5. Analysis by CPC Symbols
10.3.6. Analysis by Type of Applicant
10.3.7. Leading Industry Players: Analysis by Number of Patents
10.3.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3.9. Leading Individual Assignees: Analysis by Number of Patents
10.4. DNA Encoded Libraries: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. DNA Encoded Libraries: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. DNA Encoded Libraries Related Initiatives of Big Pharma Players
11.4. Benchmark Analysis of Big Pharma Players
11.4.1. Spider Web Analysis: AbbVie
11.4.2. Spider Web Analysis: Amgen
11.4.3. Spider Web Analysis: AstraZeneca
11.4.4. Spider Web Analysis: Bayer
11.4.5. Spider Web Analysis: Boehringer Ingelheim
11.4.6. Spider Web Analysis: Eli Lilly
11.4.7. Spider Web Analysis: GlaxoSmithKline (GSK)
11.4.8. Spider Web Analysis: Johnson & Johnson
11.4.9. Spider Web Analysis: Merck
11.4.10. Spider Web Analysis: Novartis
11.4.11. Spider Web Analysis: Pfizer
11.4.12. Spider Web Analysis: Sanofi
11.5. Concluding Remarks
12. CASE STUDY: COMPANIES / ORGANIZATIONS SUPPORTING THE DEVELOPMENT OF DNA ENCODED LIBRARIES
12.1. Chapter Overview
12.2. DNA Encoded Libraries: Overall Market Landscape of Supporting Companies / Organizations
12.2.1. Analysis by Year of Establishment
12.2.2. Analysis by Company Size
12.2.3. Analysis by Location of Headquarters
12.2.4. Analysis by Company Size and Location of Headquarters
12.2.5. Analysis by Type of Company / Organization
12.2.6. Analysis by Type of Support Services / Ancillary Tools Offered
12.2.7. Analysis by Location of Headquarters and Type of Support Services / Ancillary Tools Offered
13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global DNA Encoded Library Market (Platforms and Services): Historical, Base and Forecasted Scenario, 2017-2035
13.3.1. DNA Encoded Library Market (Platforms and Services): Distribution by Application Area, 2023 and 2035
13.3.1.1. DNA Encoded Library Market for Hit Generation / Identification, 2023-2035
13.3.1.2. DNA Encoded Library Market for Hit to Lead, 2023-2035
13.3.1.3. DNA Encoded Library Market for Hit Validation / Optimization, 2023-2035
13.3.1.4. DNA Encoded Library Market for Other Application Areas, 2023-2035
13.3.2. DNA Encoded Library Market (Platforms and Services): Distribution by Therapeutic Area, 2023 and 2035
13.3.2.1. DNA Encoded Library Market for Oncological Disorders, 2023-2035
13.3.2.2. DNA Encoded Library Market for Immunological Disorders, 2023-2035
13.3.2.3. DNA Encoded Library Market for Neurological Disorders, 2023-2035
13.3.2.4. DNA Encoded Library Market for Respiratory Disorders, 2023-2035
13.3.2.5. DNA Encoded Library Market for Dermatological Disorders, 2023-2035
13.3.2.6. DNA Encoded Library Market for Cardiovascular Disorders, 2023-2035
13.3.2.7. DNA Encoded Library Market for Infectious Diseases, 2023-2035
13.3.2.8. DNA Encoded Library Market for Other Therapeutic Areas, 2023-2035
13.3.3. DNA Encoded Library Market (Platforms and Services): Distribution by End-user, 2023 and 2035
13.3.3.1. DNA Encoded Library Market for Pharma / Biopharma Industry, 2023-2035
13.3.3.2. DNA Encoded Library Market for Academic / Research Institute, 2023-2035
13.3.3.3. DNA Encoded Library Market for Other End-users, 2023-2035
13.3.4. DNA Encoded Library Market (Platforms and Services): Distribution by Type of Payment Model Employed, 2023 and 2035
13.3.4.1. DNA Encoded Library Market: Upfront Payments, 2023-2035
13.3.4.2. DNA Encoded Library Market: Milestone Payments, 2023-2035
13.3.5. DNA Encoded Library Market (Platforms and Services): Distribution by Key Geographical Regions, 2023 and 2035
13.3.5.1. DNA Encoded Library Market in North America, 2023-2035
13.3.5.1.1. DNA Encoded Library Market in the US, 2023-2035
13.3.5.2. DNA Encoded Library Market in Europe, 2023-2035
13.3.5.2.1. DNA Encoded Library Market in Denmark, 2023-2035
13.3.5.2.2. DNA Encoded Library Market in Germany, 2023-2035
13.3.5.2.3. DNA Encoded Library Market in the UK, 2023-2035
13.3.5.2.4. DNA Encoded Library Market in Switzerland, 2023-2035
13.3.5.2.5. DNA Encoded Library Market in France, 2023-2035
13.3.5.2.6. DNA Encoded Library Market in Rest of the Europe, 2023-2035
13.3.5.3. DNA Encoded Library Market in Asia-Pacific, 2023-2035
13.3.5.3.1. DNA Encoded Library Market in China, 2023-2035
14. CONCLUDING REMARKS
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Vipergen
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Nils Jakob Vest Hansen, Chief Executive Officer
15.3. Serengen
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Thorsten Genski, Chief Executive Officer
15.4. Deluge Biotechnologies
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Thomas Kodadek, Co-Founder and Ofelia Utset, President
15.5. NovAliX
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Frank Moffatt, Director of Business Development
15.6. Orbit Discovery
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Christos Tsiamantas, Senior Scientist
15.7. Anonymous
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
